ALK-Abello AS (ALK B)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ALK-Abello AS (ALK B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012220
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ALK-Abello A/S (ALK) is a research-oriented pharmaceutical company, which discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It also markets diagnostics and other services to allergy clinics. The company’s allergy immunotherapy product portfolio includes tablet-based vaccines, sublingual or drop-based vaccines, subcutaneous vaccines; and adrenaline auto-injector to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing the ragweed, house dust mite and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, dog, venom and cat, among others. It has subsidiaries in Europe, North America, Asia-Pacific and other international markets. ALK is headquartered in Horsholm, Denmark.

ALK-Abello AS (ALK B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ALK-Abello AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
ALK-Abello AS, Medical Devices Deals, 2011 to YTD 2017 10
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
ALK-Abello AS, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Alk Abello Enters into Co-Marketing Agreement with BioCSL 12
ALK-Abello Enters into Agreement with Seqirus 13
ALK-Abello Expands Partnership with Abbott Labs 14
ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 15
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 16
Licensing Agreements 18
Japan Tobacco, Torii Pharmac Enter into Licensing Agreement with ALK-Abello 18
ALK-Abello Enters Into Licensing Agreement With Torii Pharma For Alutard And MITIZAX 19
Equity Offering 21
ALK-Abello to Raise Funds through Private Placement of AA Shares 21
ALK-Abello to Raise Funds through Private Placement of B Shares 22
ALK-Abello AS – Key Competitors 23
ALK-Abello AS – Key Employees 24
ALK-Abello AS – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Financial Announcements 27
Nov 10, 2017: ALK-Abello: Nine-month interim report (Q3) 2017 27
Aug 16, 2017: ALK-Abello: Six-month interim report (Q2) 2017 28
Aug 16, 2017: ALK: Six-month interim report (Q2) 2017 29
May 09, 2017: ALK-Abello Announces Three-month interim report (Q1) 2017 30
Feb 07, 2017: ALK releases its annual report 2016 31
Nov 10, 2016: ALK-Abello: Nine-month interim report (Q3) 2016 32
Aug 16, 2016: ALK-Abello: Six-month interim report (Q2) 2016 33
May 04, 2016: ALK-Abello: Three-month interim report 2016 34
Feb 09, 2016: ALK releases its annual report 2015 35
Corporate Communications 36
Jul 31, 2017: Management change at ALK 36
Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets 37
Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO 38
May 17, 2016: ALK appoints Carsten Hellmann as new President and CEO 39
Feb 22, 2016: ALK’s CEO Jens Bager steps down 40
Product News 41
03/01/2017: FDA approves Odactra for house dust mite allergies 41
Product Approvals 42
Mar 01, 2017: ALK Announces FDA Approval for its House Dust Mite Sublingual Allergy Immunotherapy Tablet (ACARIZAX in Europe) 42
Feb 16, 2017: ALK submits registration application for ragweed SLIT-tablet in Europe 43
Apr 13, 2016: License application for investigational house dust mite SLIT-tablet accepted for review by FDA 44
Apr 12, 2016: Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet 45
Jan 27, 2016: Marketing authorisation for ACARIZAX issued in France 46
Clinical Trials 47
Feb 27, 2017: ALKs ACARIZAX Data Results in Significant Change to the GINA Asthma Management Strategy 47
Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX 48
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
ALK-Abello AS, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ALK-Abello AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ALK-Abello AS, Deals By Therapy Area, 2011 to YTD 2017 9
ALK-Abello AS, Medical Devices Deals, 2011 to YTD 2017 10
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Alk Abello Enters into Co-Marketing Agreement with BioCSL 12
ALK-Abello Enters into Agreement with Seqirus 13
ALK-Abello Expands Partnership with Abbott Labs 14
ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 15
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 16
Japan Tobacco, Torii Pharmac Enter into Licensing Agreement with ALK-Abello 18
ALK-Abello Enters Into Licensing Agreement With Torii Pharma For Alutard And MITIZAX 19
ALK-Abello to Raise Funds through Private Placement of AA Shares 21
ALK-Abello to Raise Funds through Private Placement of B Shares 22
ALK-Abello AS, Key Competitors 23
ALK-Abello AS, Key Employees 24
ALK-Abello AS, Subsidiaries 25

★海外企業調査レポート[ALK-Abello AS (ALK B)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MegaChips Corp (6875):企業の財務・戦略的SWOT分析
    MegaChips Corp (6875) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Entasis Therapeutics Inc (ETTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, …
  • Sanofi (SAN)-医療機器分野:企業M&A・提携分析
    Summary Sanofi is a healthcare company, which focuses on researching, developing, manufacturing and marketing of a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; huma …
  • United International Enterprises Limited:企業の戦略・SWOT・財務情報
    United International Enterprises Limited - Strategy, SWOT and Corporate Finance Report Summary United International Enterprises Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Gardiner & Theobald LLP:企業の戦略的SWOT分析
    Gardiner & Theobald LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • NuScale Power LLC:企業の戦略的SWOT分析
    NuScale Power LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Indigo Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Indigo Biosciences Inc (Indigo) is a provider of preclinical contract research services for pharmaceutical research and development, biotechnology sectors. The company’s products include assay kit platforms and formats, nuclear receptor, signaling pathway, and cell viability assay products, …
  • Hotel Excelsior d.d.:企業の戦略・SWOT・財務分析
    Hotel Excelsior d.d. - Strategy, SWOT and Corporate Finance Report Summary Hotel Excelsior d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Alviva Holdings Ltd (AVV):企業の財務・戦略的SWOT分析
    Alviva Holdings Ltd (AVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cre8tek Ltd (FGO):石油・ガス:M&Aディール及び事業提携情報
    Summary Cre8tek Ltd (Cre8tek), formerly Marion Energy Ltd, is an oil and gas exploration and production company. The company explores, acquires, develops, produces and markets oil and gas. It has core operations in Clear Creek field located in the Uinta Basin. Cre8tek also holds interest in the addi …
  • Advaxis Inc (ADXS):企業の財務・戦略的SWOT分析
    Advaxis Inc (ADXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Promaxo Inc:医療機器:M&Aディール及び事業提携情報
    Summary Promaxo Inc (Promaxo) is a medical device company with focus on the development of portable MRI and other technology. The company develops and commercializes office-based, portable magnetic resonance imaging (MRI) devices that possess cellular spatial resolution, besides targeted biopsy and …
  • Corgenix Medical Corp-医療機器分野:企業M&A・提携分析
    Summary Corgenix Medical Corp (Corgenix), a subsidiary of Orgentec Diagnostika GmbH is a medical device company that offers medical diagnostic solutions. The company offers vascular disease products, infectious disease products, non-invasive liver biomarkers, and instrumentation. It offers an instru …
  • Immunomedics Inc (IMMU):医療機器:M&Aディール及び事業提携情報
    Summary Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and autoimmune disorders. The company develops its candidates based on its proprietary technol …
  • Ambry Genetics Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Ambry Genetics Corp (Ambry Genetics), a subsidiary of Konica Minolta Inc, is a provider of clinical genetic testing services. The company provides genetic diagnosis for various conditions including hereditary cancer, epilepsy, hereditary cardiovascular disease and neurodevelopmental disorder …
  • Immune Therapeutics Inc (IMUN):製薬・医療:M&Aディール及び事業提携情報
    Summary Immune Therapeutics Inc (IMUN), formerly pH Environmental Inc, is a specialty pharmaceutical company that discovers, develops and commercializes patented therapies and technology such as Lodonal, LDN, CAR-T and MENK. The company’s patented therapies are focused on the activation and re-balan …
  • Westminster Travel Limited:企業の戦略・SWOT・財務分析
    Westminster Travel Limited - Strategy, SWOT and Corporate Finance Report Summary Westminster Travel Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Moldex-Metric Inc:企業の戦略的SWOT分析
    Moldex-Metric Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Nephros Inc (NEPH):医療機器:M&Aディール及び事業提携情報
    Summary Nephros Inc (Nephros) is dialysis device manufacturer. The company offers infection control filters, dialysis ultrafilters, and hemodia filtration systems. Its dialysis ultrafilters includes Endotoxin ten Cartridge filter, SSUmini, DSU-D and SSU-D. Nephros dialysis ultrafilters are intended …
  • Go-Ahead Group Plc:企業の戦略・SWOT・財務情報
    Go-Ahead Group Plc - Strategy, SWOT and Corporate Finance Report Summary Go-Ahead Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆